Influence of hypoxia and ischemia preconditioning on bilirubin damage to astrocytes.
Hypoxia-ischemia in the perinatal period is a common cause of neurologic disability in children and is often associated with neonatal morbidity and mortality. Another frequent condition of the newborn is hyperbilirubinemia and it is well known that deposition of unconjugated bilirubin (UCB) in the central nervous system can damage nerve cells and cause encephalopathy. Interestingly, some studies report the onset of cerebral hypoxia-ischemia as a risk factor for UCB encephalopathy, since that condition often precedes neonatal hyperbilirubinemia. However, the cellular mechanisms triggered by hypoxia-ischemia that may enforce UCB deleterious effects are not well elucidated. Therefore, we designed this study to investigate whether hypoxia (HP) or combined oxygen-glucose deprivation (OGD) followed by reoxygenation, modifies glial cell susceptibility to UCB injury. Thus, cultured astrocytes were exposed to HP or OGD for 4 h and returned to normoxic conditions for another 12 h prior to incubation with UCB for 4 h. HP and OGD effects in UCB toxicity were compared to normoxic conditions. Our results demonstrate that HP and OGD preconditioning increase the vulnerability of glial cells to UCB damage by enhancing some of the deleterious effects of UCB, namely cell death by both apoptosis and necrosis. This preconditioning also augments the UCB-induced stimulation of an inflammatory response by an effect that involves the activation of the nuclear factor kappaB activation. These findings provide a novel basis for the increased risk of brain damage in jaundiced newborns that were previously exposed to hypoxia or ischemia during the perinatal period, namely during delivery.
Falcão
Ana S
AS
Centro de Patogénese Molecular-UBMBE, Faculdade de Farmácia, University of Lisbon, Av. Forças Armadas, 1600-083 Lisboa, Portugal.
Silva
Rui F M
RF
Fernandes
Adelaide
A
Brito
Maria A
MA
Brites
Dora
D
D000818:Animals; D001253:Astrocytes / Q000378:metabolism / Q000473:pathology*; D001663:Bilirubin / Q000378:metabolism*; D001921:Brain / Q000098:blood supply*; D016923:Cell Death / Q000502:physiology; D051556:Hyperbilirubinemia, Neonatal / Q000150:complications / Q000503:physiopathology; D020925:Hypoxia-Ischemia, Brain / Q000150:complications / Q000503:physiopathology*; D019194:Ischemic Preconditioning; D007647:Kernicterus / Q000150:complications / Q000503:physiopathology*; D016328:NF-kappa B / Q000378:metabolism; D051381:Rats
D016328:NF-kappa B; D001663:Bilirubin